Latest News

  • 7th September 2023

    ARECOR ANNOUNCES POSITIVE PRE-IND MEETING WITH FDA FOR NOVEL READY-TO-USE MEDICINE AT307 LICENSED TO HIKMA

  • 4th September 2023

    TETRIS PHARMA ANNOUNCES COMMERCIALISATION AGREEMENT WITH GOODLIFE

  • 17th August 2023

    ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY

News

Reset
  • 07/09/2023

    ARECOR ANNOUNCES POSITIVE PRE-IND MEETING WITH FDA FOR NOVEL READY-TO-USE MEDICINE AT307 LICENSED TO HIKMA

  • 04/09/2023

    TETRIS PHARMA ANNOUNCES COMMERCIALISATION AGREEMENT WITH GOODLIFE

  • 17/08/2023

    ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL COMPANY

  • 05/07/2023

    ARECOR ANNOUNCES ADDITIONAL AGREEMENT WITH LEADING BIOPHARMACEUTICAL COMPANY

  • 26/06/2023

    ARECOR PRESENTS POSITIVE DATA FROM US PHASE I CLINICAL TRIAL OF ULTRA-RAPID ACTING INSULIN CANDIDATE AT247 DELIVERED VIA INSULIN PUMP AT ADA ANNUAL MEETING

  • 27/06/2023

    ARECOR GRANTED KEY PATENTS IN EUROPE AND CHINA TO PROTECT PROPRIETARY INSULIN PRODUCTS

  • 15/05/2023

    TETRIS PHARMA LAUNCHES OGLUO® IN DENMARK AND NORWAY

  • 26/04/2023

    US PATENT GRANTED PROTECTING PROPRIETARY FORMULATIONS OF MONOCLONAL ANTIBODIES

  • 05/04/2023

    ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER

  • 12/03/2023

    ARECOR FEATURED IN THE MAIL ON SUNDAY’S MIDAS COLUMN

  • 22/03/2023

    FIRST PATIENT DOSED IN SECOND PHASE I CLINICAL TRIAL OF AT278

  • 16/02/2023

    ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS

  • 14/02/2023

    ARECOR STRENGTHENS COLLABORATION WITH TOP 5 GLOBAL PHARMACEUTICAL PARTNER THROUGH ADDITIONAL FORMULATION AGREEMENT

  • 30/01/2023

    ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE

  • 12/01/2023

    ARECOR ANNOUNCES TRANSFER OF AT307 TO HIKMA

  • 04/01/2023

    TETRIS PHARMA LAUNCHES OGLUO® IN AUSTRIA